Covaxin recipients to be followed-up for 3 months after 2nd dose: ICMR

Covishield has been developed by AstraZeneca and Oxford University.

Following the administration of COVID-19 vaccine 'Covaxin', the recipients will remain at the vaccination site for at least 30 minutes of the observation to record any adverse event, said the Indian Council of Medical Research (ICMR) in its guidelines for the vaccination drive.

The recipients will be followed-up for a period of three months after the second dose of vaccination, it said.

The ICMR has issued the key Standard Operating Procedure (SoP) for the restricted use authorisation of Covaxin under clinical trial mode stating, in case of severe/serious adverse event at any given point of time after vaccination, he/she will report to the nearest health facility for treatment and will also inform the designated vaccinator.

"He/she will return to the session site on day 28 or on the date given to him/her for the 2nd dose of Covaxin. All the vaccine recipients will be followed-up for a period of 3 months after the second dose of vaccination," the SoPs stated.

The individuals with the following conditions will not be eligible for vaccination -- have any history of allergies, have a fever, bleeding disorder or are on a blood thinner, are immunocompromised, or are on a medicine that affects their immune system, pregnant, breastfeeding, have received another COVID-19 vaccine, any other serious health-related issues as determined by the Vaccinator/Officer supervising vaccination.

India has given emergency use authorisation to two COVID-19 vaccines being manufactured in the country - Covishield and Covaxin. While Covishield has been developed by AstraZeneca and Oxford University, Covaxin is an indigenous vaccine developed by Bharat Biotech in collaboration with ICMR.

On January 16, Prime Minister Narendra Modi launched the world's largest vaccination drive against the pandemic.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel